{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:48:39Z","timestamp":1767167319384,"version":"build-2238731810"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The prediction of efficacy of\n                    <jats:italic>Neisseria meningitidis<\/jats:italic>\n                    serogroup B (MenB) vaccines is currently hindered due to the lack of an appropriate correlate of protection. For outer membrane vesicle (OMV) vaccines, immunogenicity has primarily been determined by the serum bactericidal antibody (SBA) assay and OMV enzyme-linked immunosorbent assay (ELISA). However, the opsonophagocytic assay (OPA), surface labeling assay, whole blood assay (WBA), and salivary antibody ELISA have been developed although correlation with protection is presently undetermined. Therefore, the aim of the study was to investigate further the usefulness of, and relationships between, MenB immunologic assays. A phase II trial of the OMV vaccine, MenBvac, with proven efficacy was initiated to compare immunologic assays incorporating the vaccine and six heterologous strains. Correlations were achieved between the SBA assay, OMV ELISA, and OPA using human polymorphonuclear leukocytes and human complement but not between an OPA using HL60 phagocytic cells and baby rabbit complement. Correlations between the surface labeling assay, the SBA assay, and the OMV ELISA were promising, although target strain dependent. Correlations between the salivary antibody ELISA and other assays were poor. Correlations to the WBA were prevented since many samples had results greater than the range of the assay. The study confirmed the immunogenicity and benefit of a third dose of MenBvac against the homologous vaccine strain using a variety of immunologic assays. These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease.\n                  <\/jats:p>","DOI":"10.1128\/iai.00466-06","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T20:24:50Z","timestamp":1153513490000},"page":"4557-4565","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":45,"title":["Comparison and Correlation of\n                    <i>Neisseria meningitidis<\/i>\n                    Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvac"],"prefix":"10.1128","volume":"74","author":[{"given":"Jamie","family":"Findlow","sequence":"first","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Taylor","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Centre for Emergency Preparedness and Response, Salisbury SP4 OJG, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audun","family":"Aase","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Horton","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, and Bristol HPA Laboratory, Bristol BS2 8HW, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Heyderman","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, and Bristol HPA Laboratory, Bristol BS2 8HW, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Southern","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Centre for Infections, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Centre for Infections, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Barchha","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewan","family":"Harrison","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Lowe","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Boxer","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Centre for Emergency Preparedness and Response, Salisbury SP4 OJG, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Heaton","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Centre for Emergency Preparedness and Response, Salisbury SP4 OJG, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Kaczmarski","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Gorringe","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Centre for Emergency Preparedness and Response, Salisbury SP4 OJG, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Centre for Infections, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.9.3531-3536.1995"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00774-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2000.1001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91961-S"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268899002915"},{"key":"e_1_3_2_7_2","first-page":"970","volume":"12","year":"2005","unstructured":"Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. H\u00f8iby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)00037-N"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.4.848"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.8.4263"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93086-3"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.5.1079"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.11.029"},{"key":"e_1_3_2_14_2","unstructured":"Findlow J. R. Barchha E. Harrison A. Lowe P. Balmer F. Sotolongo V. Weynants J. Poolman and R. Borrow. 2005. Comparison of phenotypically identical but geographically distinct Neisseria meningitidis serogroup B P1.19 15 and P1.7-2 4 isolates in the serum bactericidal antibody assay. 8th Meeting of the European Monitoring Group on Meningococci Dublin Ireland abstr. P58."},{"key":"e_1_3_2_15_2","first-page":"355","year":"1983","unstructured":"Finne, J., M. Leinonen, and P. H. M\u00e4kel\u00e4. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancetii:355-357.","journal-title":"Lancet"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00036-5"},{"key":"e_1_3_2_17_2","unstructured":"Funnell S. G. P. S. Taylor H. Pryer K. Reddin M. J. Hudson and A. R. Gorringe. 2002. Development of meningococcal whole cell antibody surface labeling and opsonophagocytic assays for assessment of vaccines containing proteins. 13th International Pathogenic Neisseria Conference Oslo Norway abstr. P251."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.4.1334-1341.1998"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/314706"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00591-1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268805004097"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.1999.0296"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0882-4010(95)90093-4"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Kaczmarski E. B. A. Birtles M. Guiver L. Newbold S. Gray T. Carr and R. Mallard. 2003. Non-culture based characterisation of Neisseria meningitidis to guide public health interventions and vaccine development. Federation of Infection Societies Seventh Conference Manchester United Kingdom.","DOI":"10.1016\/S0163-4453(02)90288-4"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08679-8"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.070"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.6.4.581-586.1999"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00324-8"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.10.4755-4761.1998"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2000.tb01493.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.10.4419-4424.1994"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200111000-00010"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00259-X"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.061"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.063"},{"key":"e_1_3_2_37_2","first-page":"689","volume":"177","year":"1998","unstructured":"Perkins, B., K. Jonsdottir, H. Breim, E. Griffiths, B. Plikaytis, E. H\u00f8iby, E. Rosenqvist, J. Holst, H. Nokleby, F. Sotolongo, G. Sierra, H. Campa, G. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. Wenger, and C. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis.177:689-691.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_38_2","first-page":"683","volume":"177","year":"1999","unstructured":"Pollard, A. J., R. Galassini, E. M. van der Voort, R. Booy, P. Langford, S. Nadel, C. Ison, J. S. Kroll, J. Poolman, and M. Levin. 1999. Humoral immune responses to Neisseria meningitidis in children. J. Infect. Dis.177:683-691.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7385.365"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02761999000400002"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.2.449"},{"key":"e_1_3_2_43_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. W. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodr\u00edguez, and M. H. Ferry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.1650-1655.2003"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.7.3775-3781.2003"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.7.3223-3231.1998"},{"key":"e_1_3_2_48_2","first-page":"1541","volume":"281","year":"1999","unstructured":"Wenger, J. D. 1999. Serogroup B meningococcal disease: new outbreaks, new strategies. JAMA281:1541-1543.","journal-title":"JAMA"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/126.5.514"}],"updated-by":[{"DOI":"10.1128\/iai.00768-07","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000}}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.00466-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.00466-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T01:45:22Z","timestamp":1646444722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.00466-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1128\/IAI.00466-06"],"URL":"https:\/\/doi.org\/10.1128\/iai.00466-06","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"2006-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-05-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}